NanoVation Therapeutics™’s Post

Check out this fresh study by Rebecca Sullivan, Savita Dhanvantari, and co-authors, driving innovation in post-myocardial infarction (MI) therapies. 🫀This research focuses on a novel PET tracer labeled with 18F, designed to track the growth hormone secretagogue receptor (GHSR) in the heart. The team developed [18F]LCE470, a quinazolinone derivative with sub-nanomolar binding affinity to GHSR – the highest known for any radiolabeled ligand of this receptor. This allows for highly sensitive and specific imaging of GHSR dynamics in the heart.  ✅ [18F]LCE470 demonstrated highest binding affinity and specificity in tracking GHSR in vivo.  ✅ Post-MI changes in GHSR distribution were detected as early as 1 day after MI, persisting throughout the 1.5-year study.  ✅ The distribution of this PET tracer occurred independently of changes in perfusion or global cardiac function, making it a robust marker for GHSR dynamics. 🛣️ This work paves the way for optimizing ghrelin-based therapeutics, potentially enhancing survival and recovery after MI. As the first tool of its kind, [18F]LCE470 could transform how we monitor and treat heart conditions following a heart attack. 📖 Learn more about the study here: https://lnkd.in/gKanAMF5 #CardiovascularResearch #MolecularImaging #PET #MIResearch #GhrelinTherapeutics #BiomedicalInnovation #WomenInSTEM

Frontage and Telomir Pharmaceuticals recently presented promising pre-clinical data for Telomir‘s lead development product at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024. The data highlighted the effect of Telomir-1 on telomere length in three human cell lines: MRC-5 fetal lung fibroblasts, human umbilical endothelial cells (HUVEC), and mesenchymal stem cells (MSC). Senior Scientist, Danielle Piazza Baker, PhD, of Frontage, presented the poster, titled “Telomir-1 Induces Telomere Extensions in Primary Human Cell Strains,” at the conference, which took place earlier this year. The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions. 👉 Learn more about this exciting news here: https://ow.ly/QcEj50R5IPL #drugdevelopment #preclinical #cro

At Cirrus Therapeutics, every day marks a new milestone in our quest to conquer age-related macular degeneration (AMD). The team's dedication to discovery comes to life in our state-of-the-art labs where collaboration meets innovation,  forging a path to groundbreaking treatments. "Working here isn’t just about the science; it’s about creating real-world solutions that will one day improve the lives of millions globally," shares Dr. Sumeet Sarin, Project Lead at Cirrus. "The energy here is electric—we're not just studying the disease, we're actively fighting it with every experiment, every breakthrough." Cirrus, born from the pioneering spirits of Cofounders Dr. Ying Kai Chan and Dr. Andrew Dick, is championing a novel approach to treating AMD by enhancing the IRAK-M protein in retinal cells, promising a significant advancement in available therapies. ➡️ Follow us on our journey as we bring visionary science from the lab to the lives of patients around the world. #vision #AMD #DryAMD #WetAMD #optometry #ophthalmology #healthcare #innovation #science #research #termeerfellow #biotech #STEM

We're here to help. At Axol, we've spent more than a decade at the forefront of iPSC technology, adding to our bank of expertise in using iPSC-derived cells for drug discovery and research. Our straightforward workflows and simple to read protocols ensure you get the best from your cells, and we are always on hand to support you in achieving your goals. Human iPSC-derived microglia are made by differentiating iPSCs from reprogrammed donor blood samples. They retain the phenotypic characteristics of the donor, producing a more human-relevant model system which opens up exciting applications of disease-derived microglia to test potential therapies in specific human disease models. Our Scientific Group Leader, Jessica Tilman PhD., is deeply involved in both microglia based product development and the delivery of service projects. Jessica works in the cellular science group, and regularly participates in custom service projects, testing compounds on healthy and disease lines for disease specific phenotypes. Jessica is happy to share her hard-won experience of working with microglia - here are her top tips: 1. Microglia are easily activated, so if you are replating, rest time is recommended before using them for assays. 2. Allow 7 days from thaw before using cells, and ensure the thawing process is as quick as possible to avoid loss of viability 3. For best results, seed cells directly onto a plate that is assay ready Click here to read the Cryopreserved Mature Microglia User Guide : https://hubs.la/Q02KPPDV0 Or click here to watch the Tech Clinic: https://hubs.la/Q02KPPKw0 If you would like to use axoCells microglia to develop human-relevant models for drug discovery and research, contact us at operations@axolbio.com #iPSCs #microglia #DrugDiscovery #StemCells #biopharma

Engineering a novel platform for extracellular vesicles-mediated mRNA delivery: in their latest work, Antje Zickler, Samir EL Andaloussi at Karolinska Institutet and collaborators designed a bioengineering platform for efficient mRNA loading and functional delivery using extracellular vesicles. This system is established by expressing a highly specific RNA-binding domain fused to CD63 in EV-producing cells, which are engineered to stably express the target mRNA https://lnkd.in/ejEcP3AC Their findings provided strong evidence that extracellular vesicles are significantly more efficient at delivering nucleic acid therapeutics compared to lipid nanoparticles (LNPs). An article co-authored by Xiuming Liang, Dhanu Gupta, Doste Mamand, Mariacristina De Luca, PhD, Giulia Corso, Lorenzo Errichelli, Justin Hean, Titash Sen, PhD, Omnia ElSharkasy, Noriyasu Kamei, Zheyu Niu, Guannan Zhou, Houze Zhou, Samantha Roudi, Oscar Wiklander, André Görgens, Joel Nordin and Virginia Castilla Llorente #extracellularvesicles #exosomes #bioengineering #mRNA #drugdelivery #Vesiculab

There are so many rodent models available for preclinical target and drug discovery for #MASH. But which model offers the highest resemblance of the human disease?   The answer is simple. In the recent issue of Nature Metabolism, the renowned #LITMUS consortium concludes that Gubra’s GAN DIO-MASH mouse model ranks #1 for human proximity, a key indicator of clinical translatability, in terms of both metabolic relevance and ability to induce MASH-fibrosis. LITMUS compared a wide range of the most commonly used preclinical MASH models, evaluating their metabolic phenotype, liver histopathology and transcriptomics against corresponding MASH patient data.    We are very proud and grateful to be recognized by LITMUS as the provider of the most translational preclinical model.   Check out the paper and explore the objective ranking of preclinical models of MASH in the industry. #PreclinicalModel #PreclincalResearch #ClinicalTranslatability #MASLD #Publication #PreclinicalCRO #ResearchModels

BIOTECanada welcomes Neurenati Therapeutics to its membership of over 240+ organizations that collectively represent the breadth of the biotechnology ecosystem, from healthcare and agriculture to biomanufacturing and investment.   Neuranati Therapeutics is a Québec-based biotech company dedicated to developing therapies for rare diseases. The first technology targets Hirschsprung disease (HSCR), a life-threatening gastrointestinal (GI) birth defect characterized by the lack of nerves in parts of the lower GI tract. Neurenati proposes an innovative therapy via growth factor to treat newborns with HSCR, thereby averting the need for surgery and its associated complications. Read more about Neuranati Therapeutics here: https://lnkd.in/eKPg498n For BIOTECanada’s full membership listing, visit: https://lnkd.in/dvc8X94n #newmember #biotechnology #biotech #canada #ecosystem #innovation #technology #quebec #rarediseases #raredisease #montreal

Join us for an insightful webinar where Daryl Cole, PhD will delve into the transformative role of stem cells in laboratory and clinical research! 🧬✨ Discover how iPSCs can be differentiated into hepatocytes using three specialized media types, each enriched with targeted growth factors and cytokines. This novel method not only simplifies the production of mature hepatic cells but also paves the way for generating human hepatic organoids—offering a robust platform for unlimited organoid development. Daryl will share a standardized workflow that leverages Research Use Only (RUO) Growth Factors and Cytokines, alongside high-throughput screening cytometry for phenotypic characterization and live-cell analysis for monitoring cell growth. This streamlined approach enhances drug discovery, development, and toxicity studies, making it easier than ever to harness the power of iPSCs. 📅 Date: November 12, 2024 🕒 Time: 11am ET Register now: https://ow.ly/TZSj50TRlg2 #StemCells #iPSCs #Hepatocytes #Organoids #DrugDiscovery #Research #Webinar #Biotech #LabResearch

Analysing MSC-extracellular vesicle angiogenic and immunomodulatory properties: Christina Holmes at Florida State University and collaborators aimed to compare the angiogenic and immunomodulatory potentials, as well as the protein and miRNA cargo compositions, of EVs derived from the two most common clinical sources of adult mesenchymal stromal/stem cells (MSC), bone marrow and adipose tissue, across various passage numbers to identify the optimal MSC source for clinically translatable EV-based therapies https://lnkd.in/eUETMypw In vitro tube formation assays using human umbilical vein endothelial cells revealed that the tissue source and passage number significantly influence the angiogenic capacity of EVs. An article co-authored by Yuan Liu, li sun and Yan Li #extracellularvesicles #exosomes #angiogenesis #multiomics #MSCs #Vesiculab

#EastMabFocus | Featured Application   🚀 Empowering Organoid Culture with Precision Proteins 🌟   Organoids are transforming biomedical research, offering unparalleled insights into human biology and disease modelling. A critical factor behind the success of organoid culture lies in the use of recombinant proteins, which provide the essential signals for stem cell growth, differentiation, and maintenance. 🧬✨   At East-Mab Bio, we specialize in high-quality, GMP-grade recombinant proteins, including R-Spondin-1, Wnt3a, and Noggin, that support the precise needs of organoid cultures. By incorporating these organoid-related proteins, researchers can better simulate in vivo-like environments, advancing discoveries in regenerative medicine, cancer research, and personalized drug testing.🔬   📩 Connect with us to learn how East-Mab Bio's products can enhance your organoid culture systems! 👉 Email: product@eastmab.com   #LifeSciences #Biotechnology #Innovation #RecombinantProteins #Organoids #BiomedicalResearch #StemCellResearch #DrugDiscovery #RegenerativeMedicine #TissueEngineering #3DCellCulture